Monopar Therapeutics Stock Price Prediction
| MNPR Stock | USD 67.44 2.85 4.05% |
Momentum 45
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.47) | EPS Estimate Current Year (1.67) | EPS Estimate Next Year (3.48) | Wall Street Target Price 112 | EPS Estimate Current Quarter (0.43) |
Using Monopar Therapeutics hype-based prediction, you can estimate the value of Monopar Therapeutics from the perspective of Monopar Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Monopar Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Monopar because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Monopar Therapeutics after-hype prediction price | USD 70.23 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Monopar Therapeutics Basic Forecasting Models to cross-verify your projections. Monopar Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Monopar Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Monopar Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Monopar Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Monopar Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Monopar Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Monopar Therapeutics' historical news coverage. Monopar Therapeutics' after-hype downside and upside margins for the prediction period are 66.61 and 73.85, respectively. We have considered Monopar Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Monopar Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Monopar Therapeutics is based on 3 months time horizon.
Monopar Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Monopar Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Monopar Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Monopar Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.33 | 3.63 | 1.23 | 0.01 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
67.44 | 70.23 | 0.09 |
|
Monopar Therapeutics Hype Timeline
Monopar Therapeutics is now traded for 67.44. The entity has historical hype elasticity of -1.23, and average elasticity to hype of competition of -0.01. Monopar is projected to decline in value after the next headline, with the price expected to drop to 70.23. The average volatility of media hype impact on the company price is about 97.06%. The price decrease on the next news is expected to be -0.09%, whereas the daily expected return is now at -0.33%. The volatility of related hype on Monopar Therapeutics is about 8066.67%, with the expected price after the next announcement by competition of 67.43. About 24.0% of the company outstanding shares are owned by corporate insiders. The book value of Monopar Therapeutics was now reported as 21.25. The company recorded a loss per share of 3.96. Monopar Therapeutics had not issued any dividends in recent years. The entity had 1:5 split on the 13th of August 2024. Given the investment horizon of 90 days the next projected press release will be in about 8 days. Check out Monopar Therapeutics Basic Forecasting Models to cross-verify your projections.Monopar Therapeutics Related Hype Analysis
Having access to credible news sources related to Monopar Therapeutics' direct competition is more important than ever and may enhance your ability to predict Monopar Therapeutics' future price movements. Getting to know how Monopar Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Monopar Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CMPX | Compass Therapeutics | 0.16 | 9 per month | 3.19 | 0.16 | 7.61 | (5.86) | 16.90 | |
| FDMT | 4D Molecular Therapeutics | 0.11 | 12 per month | 0.00 | (0.04) | 8.07 | (9.30) | 33.45 | |
| BCYC | Bicycle Therapeutics | (0.13) | 9 per month | 0.00 | (0.07) | 6.06 | (5.88) | 17.28 | |
| FULC | Fulcrum Therapeutics | (0.59) | 12 per month | 4.50 | 0.06 | 11.56 | (7.84) | 53.80 | |
| GOSS | Gossamer Bio | (0.24) | 10 per month | 4.40 | 0.06 | 9.59 | (6.57) | 31.39 | |
| LXRX | Lexicon Pharmaceuticals | (0.02) | 8 per month | 3.84 | 0.07 | 9.86 | (6.49) | 26.73 | |
| OMER | Omeros | 0.39 | 8 per month | 4.35 | 0.10 | 12.62 | (7.99) | 87.69 | |
| KALV | Kalvista Pharmaceuticals | 0.07 | 7 per month | 3.21 | 0.1 | 8.43 | (5.92) | 25.15 | |
| AKBA | Akebia Ther | (0.09) | 10 per month | 0.00 | (0.19) | 5.24 | (6.25) | 36.66 | |
| NMRA | Neumora Therapeutics | (0.11) | 7 per month | 3.96 | 0.07 | 13.85 | (7.30) | 42.94 |
Monopar Therapeutics Additional Predictive Modules
Most predictive techniques to examine Monopar price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Monopar using various technical indicators. When you analyze Monopar charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Monopar Therapeutics Predictive Indicators
The successful prediction of Monopar Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Monopar Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Monopar Therapeutics based on analysis of Monopar Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Monopar Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Monopar Therapeutics's related companies.
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Monopar Stock
Moving against Monopar Stock
| 0.85 | VNDA | Vanda Pharmaceuticals | PairCorr |
| 0.81 | CAPR | Capricor Therapeutics | PairCorr |
| 0.69 | MARUF | Marubeni Earnings Call This Week | PairCorr |
| 0.68 | DBVT | DBV Technologies | PairCorr |
| 0.67 | CNOB | ConnectOne Bancorp Earnings Call Tomorrow | PairCorr |
| 0.61 | LYEL | Lyell Immunopharma | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.